Millennium Management 13F: Cuts ABVX Stake by $18M
Millennium Management pared back its holdings in biotechnology firm ABIVAX Société Anonyme during the reporting period.
Reviewed by automated data checks against the source filing. How we make and check alerts
Millennium Management sold 135,068 shares from its stake in ABIVAX Société Anonyme ($ABVX), an 18.23% decrease, according to a 13F filing with the SEC dated May 15, 2026. It reported 605,992 shares worth $80.49 million at the end of the quarter.
Since the filing, $ABVX is up 6.5% after 1 week, down 14.2% after 1 month and down 23.1% to date (from the $114.53 close on May 15, 2026).
Find the original: Millennium Management 13F filings on SEC EDGAR
ABVX
ABIVAX Société Anonyme
Key Points
- Millennium Management cut its position in ABIVAX Société Anonyme by 135,068 shares, bringing its total holdings to 605,992 shares valued at roughly $80.5 million.
- The biotechnology company trades near $132.83, sitting well within its 52-week range of $69.81 to $148.83.
- Wall Street analysts hold a strong buy consensus on the stock with an average price target of $163.58 across 12 tracking firms.
Get $ABVX trade alerts by text
We text you when insiders, Congress or big funds trade $ABVX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated ABIVAX Société Anonyme alert may contain errors. Disclosures
Millennium Management Trims ABIVAX Holdings
Millennium Management reduced its stake in ABIVAX Société Anonyme (NasdaqGM: ABVX) by 18.2% during the quarter ended May 15, 2026, according to a recent Form 13F filing with the SEC. The fund sold 135,068 shares during the period, leaving it with 605,992 shares. Based on the market price around the filing, that remaining stake carried an estimated value of $80.5 million. This transaction follows other recent portfolio adjustments among institutional holders, such as Lmr Partners and Walleye Trading trimming their own positions earlier in May.
Millennium Management vs. the S&P 500
Hypothetical returns from Millennium Management's disclosed trades, not real profit or advice. How we model this.
Stock Performance and Valuation Context
Shares of ABIVAX changed hands at $132.83 on Wednesday. The company has a market capitalization of roughly $8.06 billion. Its stock price moves between a 52-week low of $69.81 and a 52-week high of $148.83. The equity currently trades above its 50-day moving average of $108.41 and its 200-day moving average of $116.29. Because the clinical-stage firm is pre-profit, it does not carry a positive price-to-earnings ratio.
Analysts Set New Price Targets
Several research firms updated their views on ABVX over recent months. On September 22, 2026, Truist Securities kept a Buy rating while shifting its target to $151.00 from $155.00, and Wedbush maintained a Neutral rating with a target cut to $118.00 from $140.00. Earlier, on September 10, 2026, Goldman Sachs launched coverage with a Buy rating and a $155.00 target. BTIG reiterated a Buy rating at a $175.00 target on September 5, 2026. Piper Sandler adjusted its target to $175.00 while keeping an Overweight rating on July 9, 2026, and Citizens reaffirmed a Market Outperform rating with a $187.00 target on July 1, 2026.
About ABIVAX Société Anonyme
Based in Paris, France, ABIVAX Société Anonyme operates as a clinical-stage biotechnology enterprise. The team focuses on developing treatments that leverage the body's natural regulatory systems to calm immune responses in patients with chronic inflammatory conditions. Its primary drug candidate, obefazimod, is advancing through Phase 3 trials for ulcerative colitis alongside Phase 2b evaluations for Crohn's disease.
What to Watch at ABIVAX Société Anonyme
Investors will look toward upcoming clinical pipeline updates and the next scheduled earnings report on March 22, 2027. Remember that 13F filings are backward-looking documents capturing snapshots of institutional ownership on specific dates and may not reflect current trading activity today.
Related Filing Alerts
Source: Millennium Management's 13F filing on $ABVX (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Millennium Management 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts